Cassava Sciences (SAVA) is a clinical-stage biotechnology company, engaged in the detection and treatments of neurodegenerative diseases, such as Alzheimer's disease. George Tsilis joins Alex Coffey and Jenny Horne to discuss SAVA as the stock is up nearly 60% from its 52-week low. He talks about how SAVA's Alzheimer's drug Simufilam showed results that it slowed cognitive decline in a small Alzheimer’s disease trial. Tune in to find out more about the stock market today.
05 Jul 2023
Morning Trade Live
15 Sep 2023
Market On Close
24 Oct 2023
Market On Close
30 Nov 2023
The Watch List
21 Sep 2023
Trading 360
09 Nov 2023
The Watch List
02 Oct 2023